Loading…
← CockpitCompetitor Analysis › 9606.HK Duality Biotherapeutics, Inc.Open in the cockpit ↗

Duality Biotherapeutics, Inc.9606.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology

Chinese biotech developing antibody-drug conjugates for cancer, with licensing deals with Merck, BMS and Novartis.

≈ A Chinese Seagen/ImmunoGen-style ADC developerMomentum laggard 3
Mkt cap
$1.06B
US dollars, full cap
Free float
70%
of shares outstanding
$/day
$20.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 12.9%
Hurdle
n/a
no reverse DCF
Next earnings
125 days
23 Mar 2027
Close · HKDHK$91.10
1D-2.3%
1W-16.0%
1M-46.0%
3M-49.8%
6M-57.7%
YTD-69.5%
1Y-69.6%
ATR %10.4%
52w lowhigh75.8% off high

What Duality Biotherapeutics does

Chinese biotech developing antibody-drug conjugates for cancer, with licensing deals with Merck, BMS and Novartis.

No product sales yet: income is upfront payments and milestones from drug partners that license its ADCs (antibody-drug conjugates, which carry a toxic payload to cancer cells), and the cash from those deals funds its own trials. BioNTech holds rights to its two lead ADCs.

In one line: A Chinese Seagen/ImmunoGen-style ADC developer.

Products and services

  • ADC oncology pipeline
  • ADC linker/payload technology platform

Customers

  • Merck
  • Bristol Myers Squibb
  • Novartis

Where it sits in the supply chain

  • Biopharmaceuticals
  • ADC drug discovery & development
  • Out-licensing to global pharma

What could go right

  • Global pharma licensing/milestone payments
  • Expanding ADC pipeline into new tumor types

What could go wrong

  • Clinical trial failure risk
  • Dependence on licensing deal milestones

Moat: narrow (IP / patents, process know-how). Differentiated ADC linker-payload technology validated by multiple global pharma licensing deals.

Headquarters: Shanghai, China · Employees: 231

Named competitors

Duality Biotherapeutics at a glance

Size Duality Biotherapeutics (9606.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $1.06B, the 571st largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$91.10 on 18 Nov 2026.

Performance Over six months the shares fell 57.7%, against -16.6% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — lowest of 20 in its peer set.

Growth Revenue fell 4.6% over the last twelve months (peer median +1.1%); the operating margin is -180.6% (peer median -2.5%).

Valuation It trades at 5.6× enterprise value to sales against a peer median of 6.2× (7th cheapest of 14).

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

40608010021 May 202621 Aug 202618 Nov 2026Peer median 839606.HK 40
Six months, rebased to 100: Duality Biotherapeutics against the median of its 20 peers (local-currency closes).

Duality Biotherapeutics financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$932MHK$2.01BHK$2.10BHK$1.97BHK$1.86M
Revenue growth—-5%+7%+106,001%—
Gross profit-HK$276MHK$631MHK$842MHK$1.50B-HK$226,761
EBITDA-HK$1.67B-HK$489M-HK$220MHK$820M-HK$428M
Net income-HK$1.62B-HK$2.81B-HK$1.14B-HK$395M-HK$450M
Free cash flow-HK$921MHK$197MHK$308MHK$890M-HK$351M
Capital expenditureHK$18.6MHK$14.9MHK$33.8MHK$39.7MHK$25.8M
Total debtn/aHK$181MHK$3.25BHK$2.35BHK$1.21B

Quarterly statements and history in the cockpit →

Duality Biotherapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-40%-20%0%JBIO002030300482ANROVORINBXSGP688276CMPSAKUMSMLYS688739600195688253ODTX30120721609606.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Duality Biotherapeutics is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%0×200×400×002030300482INBX688276AKUMS688739688253ODTX21609606.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Duality Biotherapeutics is the large dot.

Duality Biotherapeutics competitors and peer comparison

Head to head with its named competitors (9606.HK vs 1801.HK vs 9995.HK vs 6990.HK)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Duality Biotherapeutics 9606.HK$1.06B-58%-5%-181%5.6×n/a
Innovent Biologics 1801.HK$18.9B+4%+43%17%7.3×11.6%
RemeGen 9995.HK$6.07B-28%+293%61%4.4×-6.8%
Sichuan Kelun-Biotech Biopharmaceutical 6990.HK$13.0B-1%+44%-38%41.4×55.3%

How Duality Biotherapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Duality Biotherapeutics against its 20 peers (data as of 18 Nov 2026)
Measure9606.HKPeer medianRank in peer set
1-month return-46.0%-8.6%lowest of 21
6-month return-57.7%-16.6%lowest of 20
Distance from 52-week high-75.8%-40.8%lowest of 21
Revenue growth (TTM)-4.6%+1.1%6th lowest of 14
Operating margin-180.6%-2.5%3rd lowest of 14
EV / Sales5.6×6.2×7th cheapest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Duality Biotherapeutics 9606.HKHong Kong$1.06B-58%-5%-181%5.6×n/an/a
Jade Biosciences JBIOUnited States$1.07B-34%n/an/an/an/an/a
Daan Gene 002030.SZChina$1.05B-17%+1%-81%8.0×4.8%-32.3%
Guangzhou Wondfo Biotech 300482.SZChina$1.05B-18%-24%-2%2.9×14.3%-5.8%
Alto Neuroscience ANROUnited States$1.04B+25%n/an/an/an/an/a
Vor Biopharma VORUnited States$1.10B+15%n/an/an/an/an/a
Inhibrx Biosciences INBXUnited States$1.02B-37%+43%-6,287%551.0×n/an/a
SpyGlass Pharma SGPUnited States$993M+36%n/an/an/an/an/a
Changchun BCHT Biotechnology 688276.SSChina$992M-2%+2%-29%9.9×n/an/a
COMPASS Pathways Plc Sponsored ADR CMPSUnited States$1.15B-25%n/an/an/an/an/a
Kardigan KARDUnited States$1.15Bn/an/an/an/an/an/a
Akums Drugs and Pharmaceuticals AKUMS.NSIndia$1.21B+38%+18%10%2.0×15.3%+9.9%
Mineralys Therapeutics MLYSUnited States$1.22B-52%n/an/an/an/an/a
Liaoning Chengda Biotechnology 688739.SSChina$1.22B-14%-9%0%2.2×6.6%-7.0%
China Animal Husbandry Industry 600195.SSChina$921M-16%+1%2%1.3×6.1%+4.4%
Innovita Biological Technology 688253.SSChina$915M-28%-28%11%14.0×39.6%-16.6%
Odyssey Therapeutics ODTXUnited States$912M+12%-33%-5,415%204.9×n/an/a
Pacific Shuanglin Bio-pharmacy 000403.SZChina$1.24B-21%+1%10%3.5×n/an/a
Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZChina$909M-15%0%22%4.2×9.2%+2.3%
Hualan Biological Vaccine 301207.SZChina$1.25B-29%-28%-7%9.0×33.2%-13.1%
GNI 2160.TJapan$903M-25%+44%-21%6.2×n/an/a

Questions

Who are Duality Biotherapeutics's main competitors?
Named competitors: Innovent Biologics (1801.HK), RemeGen (9995.HK), Sichuan Kelun-Biotech (6990.HK). The cockpit's measured peer set (industry) also includes Jade Biosciences (JBIO), Daan Gene (002030.SZ), Guangzhou Wondfo Biotech (300482.SZ), Alto Neuroscience (ANRO), Vor Biopharma (VOR), Inhibrx Biosciences (INBX).
Is Duality Biotherapeutics expensive compared with its peers?
On ev / sales it trades at 5.6× against a peer median of 6.2×, 7th cheapest of 14 in its peer set.
How has Duality Biotherapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -57.7% against -16.6% for the median peer; over one year -69.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.